{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:04:47Z","timestamp":1791201887757,"version":"4.2.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,4,24]],"date-time":"2011-04-24T00:00:00Z","timestamp":1303603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00280-011-1620-1","type":"journal-article","created":{"date-parts":[[2011,4,24]],"date-time":"2011-04-24T05:05:04Z","timestamp":1303621504000},"page":"547-552","source":"Crossref","is-referenced-by-count":67,"title":["Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer"],"prefix":"10.1007","volume":"68","author":[{"given":"Peter D.","family":"Boasberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bodkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris R.","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro D.","family":"Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,24]]},"reference":[{"key":"1620_CR1","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","volume":"23","author":"PM Lorusso","year":"2005","unstructured":"Lorusso PM, Adjei AA, Varterasian M et al (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281\u20135293. doi: 10.1200\/JCO.2005.14.415","journal-title":"J Clin Oncol"},{"key":"1620_CR2","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/nsmb859","volume":"11","author":"JF Ohren","year":"2004","unstructured":"Ohren JF, Chen H, Pavlovsky A et al (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11:1192\u20131197. doi: 10.1038\/nsmb859","journal-title":"Nat Struct Mol Biol"},{"key":"1620_CR3","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","volume":"22","author":"J Rinehart","year":"2004","unstructured":"Rinehart J, Adjei AA, Lorusso PM et al (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456\u20134462. doi: 10.1200\/JCO.2004.01.185","journal-title":"J Clin Oncol"},{"key":"1620_CR4","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291\u20133310. doi: 10.1038\/sj.onc.1210422","journal-title":"Oncogene"},{"key":"1620_CR5","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/sj.onc.1210394","volume":"26","author":"MM McKay","year":"2007","unstructured":"McKay MM, Morrison DK (2007) Integrating signals from RTKs to ERK\/MAPK. Oncogene 26:3113\u20133121. doi: 10.1038\/sj.onc.1210394","journal-title":"Oncogene"},{"key":"1620_CR6","doi-asserted-by":"crossref","first-page":"14373","DOI":"10.1016\/S0021-9258(19)49722-6","volume":"267","author":"R Seger","year":"1992","unstructured":"Seger R, Ahn NG, Posada J et al (1992) Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J Biol Chem 267:14373\u201314381","journal-title":"J Biol Chem"},{"key":"1620_CR7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.onc.1202367","volume":"18","author":"R Hoshino","year":"1999","unstructured":"Hoshino R, Chatani Y, Yamori T et al (1999) Constitutive activation of the 41-\/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813\u2013822","journal-title":"Oncogene"},{"key":"1620_CR8","first-page":"614","volume":"9","author":"JA McCubrey","year":"2008","unstructured":"McCubrey JA, Milella M, Tafuri A et al (2008) Targeting the Raf\/MEK\/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 9:614\u2013630","journal-title":"Curr Opin Investig Drugs"},{"key":"1620_CR9","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1158\/1078-0432.CCR-08-0333","volume":"14","author":"JS Sebolt-Leopold","year":"2008","unstructured":"Sebolt-Leopold JS (2008) Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 14:3651\u20133656. doi: 10.1158\/1078-0432.CCR-08-0333","journal-title":"Clin Cancer Res"},{"key":"1620_CR10","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-09-1883","volume":"16","author":"PM Lorusso","year":"2010","unstructured":"Lorusso PM, Krishnamurthi SS, Rinehart JJ et al (2010) Phase I pharmacokinetic and pharmacodynamic study of the oral MEK inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16:1924\u20131937. doi: 10.1158\/1078-0432.CCR-09-1883","journal-title":"Clin Cancer Res"},{"key":"1620_CR11","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>3.0.CO;2-1","volume":"16","author":"TT Chen","year":"1997","unstructured":"Chen TT (1997) Optimal three-stage designs for phase II cancer clinical trials. Stat Med 16:2701\u20132711. doi: 10.1002\/(SICI)1097-0258(19971215)16:23<2701:AID-SIM704>3.0.CO;2-1","journal-title":"Stat Med"},{"key":"1620_CR12","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","volume":"26","author":"AA Adjei","year":"2008","unstructured":"Adjei AA, Cohen RB, Franklin W et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139\u20132146. doi: 10.1200\/JCO.2007.14.4956","journal-title":"J Clin Oncol"},{"key":"1620_CR13","doi-asserted-by":"crossref","unstructured":"Agarwal R, Banerji U, Camidge DR et al (2008) The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): a phase I trial in patients (pts) with advanced cancer. J Clin Oncol 26:15S (supplement; abstract 3535)","DOI":"10.1200\/jco.2008.26.15_suppl.3535"},{"key":"1620_CR14","doi-asserted-by":"crossref","unstructured":"Lang I, Adenis A, Boer K et al (2008) AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy. J Clin Oncol 26:15S (supplement; abstract 4114)","DOI":"10.1200\/jco.2008.26.15_suppl.4114"},{"key":"1620_CR15","doi-asserted-by":"crossref","unstructured":"Dummer R, Robert C, Chapman PB et al (2008) AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. J Clin Oncol 26:15S (supplement; abstract 9033)","DOI":"10.1200\/jco.2008.26.15_suppl.9033"},{"key":"1620_CR16","doi-asserted-by":"crossref","unstructured":"Tzekova V, Cebotaru C, Ciuleanu TE et al (2008) Efficacy and safety of AZD6244 (ARRY-142886) as second\/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26:15S (supplement; abstract 8029)","DOI":"10.1200\/jco.2008.26.15_suppl.8029"},{"key":"1620_CR17","doi-asserted-by":"crossref","unstructured":"Lucas AS, Cohen EE, Cohen RB et al (2010) Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. J Clin Oncol 28:15s (supplement; abstract 5536)","DOI":"10.1200\/jco.2010.28.15_suppl.5536"},{"key":"1620_CR18","doi-asserted-by":"crossref","unstructured":"Delord J, Houede N, Awada A et al (2010) First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors. J Clin Oncol 28:15s (supplement; abstract 2504)","DOI":"10.1200\/jco.2010.28.15_suppl.2504"},{"key":"1620_CR19","doi-asserted-by":"crossref","unstructured":"Infante JR, Fecher LA, Nallapareddy S et al (2010) Safety and efficacy results from the first-in-human study of the oral MEK 1\/2 inhibitor GSK1120212. J Clin Oncol 28:15s (supplement; abstract 2503)","DOI":"10.1200\/jco.2010.28.15_suppl.2503"},{"key":"1620_CR20","doi-asserted-by":"crossref","unstructured":"Borad MJ, Akerele CE, Ramanathan RK et al (2010) Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors. J Clin Oncol 28:15s (supplement; abstract 2505)","DOI":"10.1200\/jco.2010.28.15_suppl.2505"},{"key":"1620_CR21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bcp.2004.04.024","volume":"68","author":"ET Keller","year":"2004","unstructured":"Keller ET, Fu Z, Brennan M (2004) The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol 68:1049\u20131053. doi: 10.1016\/j.bcp.2004.04.024","journal-title":"Biochem Pharmacol"},{"key":"1620_CR22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1212\/WNL.46.4.917","volume":"46","author":"JS Katz","year":"1996","unstructured":"Katz JS, Wolfe GI, Burns DK, Bryan WW, Fleckenstein JL, Barohn RJ (1996) Isolated neck extensor myopathy: a common cause of dropped head syndrome. Neurology 46:917\u2013921","journal-title":"Neurology"},{"key":"1620_CR23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.55.6.896-a","volume":"55","author":"H Askmark","year":"2000","unstructured":"Askmark H, Olsson Y, Rossitti S (2000) Treatable dropped head syndrome in hypothyroidism. Neurology 55:896\u2013897","journal-title":"Neurology"},{"key":"1620_CR24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1054\/jocn.1999.0209","volume":"7","author":"KJ Goh","year":"2000","unstructured":"Goh KJ, Wong KT, Tan CT (2000) Myopathic dropped head syndrome: a syndrome of mixed aetiology. J Clin Neurosci 7:334\u2013336","journal-title":"J Clin Neurosci"},{"key":"1620_CR25","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1007\/s00415-002-0898-7","volume":"249","author":"R Beekman","year":"2002","unstructured":"Beekman R, Tijssen CC, Visser LH, Schellens RL (2002) Dropped head as the presenting symptom of primary hyperparathyroidism. J Neurol 249:1738\u20131739. doi: 10.1007\/s00415-002-0898-7","journal-title":"J Neurol"},{"key":"1620_CR26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1042\/BST0341287","volume":"34","author":"K Frebel","year":"2006","unstructured":"Frebel K, Wiese S (2006) Signalling molecules essential for neuronal survival and differentiation. Biochem Soc Trans 34:1287\u20131290","journal-title":"Biochem Soc Trans"},{"key":"1620_CR27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/dbio.2002.0736","volume":"248","author":"A Galy","year":"2002","unstructured":"Galy A, Neron B, Planque N, Saule S, Eychene A (2002) Activated MAPK\/ERK kinase (MEK-1) induces transdifferentiation of pigmented epithelium into neural retina. Dev Biol 248:251\u2013264. doi: 10.1006\/dbio.2002.0736","journal-title":"Dev Biol"},{"key":"1620_CR28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/0470846674.ch13","volume":"239","author":"RD Fields","year":"2001","unstructured":"Fields RD, Eshete F, Dudek S, Ozsarac N, Stevens B (2001) Regulation of gene expression by action potentials: dependence on complexity in cellular information processing. Novartis Found Symp 239:160\u2013172","journal-title":"Novartis Found Symp"},{"key":"1620_CR29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1460-9568.2000.00010.x","volume":"12","author":"W Ma","year":"2000","unstructured":"Ma W, Maric D, Li BS et al (2000) Acetylcholine stimulates cortical precursor cell proliferation in vitro via muscarinic receptor activation and MAP kinase phosphorylation. Eur J Neurosci 12:1227\u20131240. doi: 10.1046\/j.1460-9568.2000.00010.x","journal-title":"Eur J Neurosci"},{"key":"1620_CR30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1152\/japplphysiol.00085.2007","volume":"103","author":"HF Kramer","year":"2007","unstructured":"Kramer HF, Goodyear LJ (2007) Exercise, MAPK, and NF-kappaB signaling in skeletal muscle. J Appl Physiol 103:388\u2013395. doi: 10.1152\/japplphysiol.00085.2007","journal-title":"J Appl Physiol"},{"key":"1620_CR31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1024119224033","volume":"247","author":"T Ravingerova","year":"2003","unstructured":"Ravingerova T, Barancik M, Strniskova M (2003) Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 247:127\u2013138. doi: 10.1023\/A:1024119224033","journal-title":"Mol Cell Biochem"},{"key":"1620_CR32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00280-006-0323-5","volume":"59","author":"AP Brown","year":"2007","unstructured":"Brown AP, Carlson TC, Loi CM, Graziano MJ (2007) Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol 59:671\u2013679. doi: 10.1007\/s00280-006-0323-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"1620_CR33","doi-asserted-by":"crossref","unstructured":"Rosen LS, Galatin P, Fehling JM et al (2008) A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors. J Clin Oncol 26:15S (supplement; abstract 14585)","DOI":"10.1200\/jco.2008.26.15_suppl.14585"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1620-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1620-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1620-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T03:19:58Z","timestamp":1637551198000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1620-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,24]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["1620"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1620-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,24]]}}}